Your browser doesn't support javascript.
loading
SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer.
Simmler, Patrik; Cortijo, Cédric; Koch, Lisa Maria; Galliker, Patricia; Angori, Silvia; Bolck, Hella Anna; Mueller, Christina; Vukolic, Ana; Mirtschink, Peter; Christinat, Yann; Davidson, Natalie R; Lehmann, Kjong-Van; Pellegrini, Giovanni; Pauli, Chantal; Lenggenhager, Daniela; Guccini, Ilaria; Ringel, Till; Hirt, Christian; Marquart, Kim Fabiano; Schaefer, Moritz; Rätsch, Gunnar; Peter, Matthias; Moch, Holger; Stoffel, Markus; Schwank, Gerald.
Afiliação
  • Simmler P; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland.
  • Cortijo C; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
  • Koch LM; Institute of Biochemistry, ETH Zurich, 8093 Zurich, Switzerland.
  • Galliker P; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
  • Angori S; Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Bolck HA; Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Mueller C; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
  • Vukolic A; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
  • Mirtschink P; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
  • Christinat Y; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
  • Davidson NR; Department of Computer Science, ETH Zurich, 8092 Zurich, Switzerland.
  • Lehmann KV; Department of Computer Science, ETH Zurich, 8092 Zurich, Switzerland.
  • Pellegrini G; Institute of Veterinarian Science, University of Zurich, 8057 Zurich, Switzerland.
  • Pauli C; Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Lenggenhager D; Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Guccini I; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
  • Ringel T; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland.
  • Hirt C; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland.
  • Marquart KF; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland.
  • Schaefer M; Medical University of Vienna, Center for Medical Statistics, Informatics and Intelligent Systems (CeMSIIS), Institute of Artificial Intelligence, 1090 Vienna, Austria.
  • Rätsch G; Department of Computer Science, ETH Zurich, 8092 Zurich, Switzerland.
  • Peter M; Institute of Biochemistry, ETH Zurich, 8093 Zurich, Switzerland.
  • Moch H; Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091 Zurich, Switzerland.
  • Stoffel M; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland.
  • Schwank G; Institute of Molecular Health Sciences, ETH Zurich, 8093 Zurich, Switzerland; Institute of Pharmacology and Toxicology, University of Zurich, 8057 Zurich, Switzerland. Electronic address: schwank@pharma.uzh.ch.
Cell Rep ; 40(8): 111266, 2022 08 23.
Article em En | MEDLINE | ID: mdl-36001976
ABSTRACT
Mutations in the splicing factor SF3B1 are frequently occurring in various cancers and drive tumor progression through the activation of cryptic splice sites in multiple genes. Recent studies also demonstrate a positive correlation between the expression levels of wild-type SF3B1 and tumor malignancy. Here, we demonstrate that SF3B1 is a hypoxia-inducible factor (HIF)-1 target gene that positively regulates HIF1 pathway activity. By physically interacting with HIF1α, SF3B1 facilitates binding of the HIF1 complex to hypoxia response elements (HREs) to activate target gene expression. To further validate the relevance of this mechanism for tumor progression, we show that a reduction in SF3B1 levels via monoallelic deletion of Sf3b1 impedes tumor formation and progression via impaired HIF signaling in a mouse model for pancreatic cancer. Our work uncovers an essential role of SF3B1 in HIF1 signaling, thereby providing a potential explanation for the link between high SF3B1 expression and aggressiveness of solid tumors.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Transdução de Sinais Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Transdução de Sinais Idioma: En Ano de publicação: 2022 Tipo de documento: Article